Becton Dickinson Settles SEC Alaris Case, Faces Bard PowerPort Verdict

Simply Wall St··US·Read original
3▲0 ▼0Impact / 5
Summary · why it matters

Becton Dickinson reached an SEC cease and desist settlement over past Alaris infusion pump risk disclosures, including a civil penalty and the creation of a Fair Fund for investors. The company's subsidiary C.R. Bard also recently faced a plaintiff verdict in the Bard PowerPort litigation, with almost 4,000 related federal product liability cases still pending. Both matters feed into a wider pattern of legal and compliance pressures around the company's Alaris and Bard PowerPort platforms. The clearest marker to watch is how Becton Dickinson quantifies Alaris related and Bard PowerPort legal costs in upcoming SEC filings, especially any updated provisions or ranges of reasonably possible losses in notes to the accounts over the next few reporting periods.

Impact on assets 1

Biotech & Genomic Medicine▲ · 1 stocks
© 2026 MarketIVNews